Mostrar el registro sencillo del ítem

Mutación BRAFV600E en citología tiroidea preoperatoria como identificador del compromiso ganglionar de compartimento central de los pacientes con carcinoma papilar de tiroides Bethesda V y VI

dc.contributor.advisorcadena piñeros, enriquespa
dc.contributor.authorMogollon Reyes, Geanny
dc.contributor.otherRomero, alfredospa
dc.contributor.otherrojas, andresspa
dc.coverage.spatialMedicinaspa
dc.date.accessioned2019-02-06T18:51:14Z
dc.date.accessioned2019-12-30T18:58:36Z
dc.date.available2019-02-06T18:51:14Z
dc.date.available2019-12-30T18:58:36Z
dc.date.issued2017-11-28
dc.identifier.urihttp://hdl.handle.net/10654/20395
dc.description.abstractEl carcinoma papilar de tiroides es el tipo de cáncer endocrino más común, siendo este el 85% de los tumores de tiroides, al momento del diagnóstico hasta el 45% de los pacientes tienen compromiso ganglionar el cual tiene gran influencia en la persistencia y recurrencia de la enfermedad y hasta el 60 % del compartimiento central. El BRAF es una mutación que se presenta en la mitad de los carcinomas papilares de tiroides, altamente especifico y se correlaciona con la agresividad, recurrencia y mortalidad del carcinoma, lo que resalta la importancia de conocer el estatus de mismo en los pacientes. En paciente con carcinoma papilar de tiroides determinar la presencia de BRAF positivo llevara a la necesidad de vaciamiento central ganglionar. No hay estudios previos de la prueba de BRAF en citología y su correlación con ganglios positivos en el vaciamiento central en cuello.spa
dc.description.tableofcontentsTABLA DE CONTENIDO pág. 1. INFORMACIÓN GENERAL DEL PROYECTO………………………………….3 1.1 TITULO GENERAL DEL PROYECTO…………………………………….……4 1.2 INVESTIGADOR PRINCIPAL…………………………………………..……….4 1.3 INVESTIGADORES SECUNDARIOS………………………………….……….4 2. RESUMEN EJECUTIVO…………………………………………………..……….4 2.1 PROBLEMA………………………………………………………………………..4 2.2 OBJETIVO GENERAL………………………………………………………...….5 2.3 MATERIALES Y MÉTODOS……………………………………………….…….5 3. PLANTEAMIENTO DEL PROBLEMA Y JUSTIFICACIÓN……………….……7 4. OBJETIVOS GENERALES Y ESPECÍFICOS…………………………….....….9 4.1 OBJETIVO GENERAL……………………………………………………………9 4.2 OBJETIVOS ESPECIFICOS………………………………………………..……9 5. MARCO TEÓRICO………………………………………………………………..10 5.1 ANTECEDENTES…………………………………………………………...…..10 5.2 TRATAMIENTO QUIRÚRGICO………………………………………………..13 6. METODOLOGÍA………………………………………………………….……….15 6.1 HIPÓTESIS OPERATIVAS……………………………………………………..15 6.2 DEFINICIÓN DE SUJETOS DE ESTUDIO…………………………………...15 6.3 CRITERIOS DE INCLUSIÓN…………………………………………………..15 6.4 CRITERIOS EXCLUSIÓN………………………………………………...…....16 6.5 TAMAÑO DE MUESTRA……………………………………………….………16 6.6. DESCRIPCIÓN DE LAS INTERVENCIONES………………………….……16 6.7. PROCEDIMIENTOS………………………………………………...………….17 6.8. PLAN DE ANÁLISIS………………………………………………...………….17 6.9 VARIABLES……………………………………………………….….………….18 7. CONDUCCIÓN DEL ESTUDIO………………………………………….………20 7.1. SITIO DE INVESTIGACIÓN………………………………………….………..20 7.2. MANEJO DE SUSTANCIAS O ESPECÍMENES BIOLÓGICOS…….…….20 7.3. ARCHIVO DE DATOS Y SISTEMATIZACIÓN…………………...………….20 7.4. CONSIDERACIONES ÉTICAS………………………….……………….……20 7.5. SEGURIDAD…………………………………………………………………….21 7.6. CONSIDERACIONES AMBIENTALES……………………….………………21 7.7. CONFIDENCIALIDAD………………………………………………………….21 7.8. ASEGURAMIENTO Y CONTROL DE LA CALIDAD………………………..22 8. RESULTADOS/PRODUCTOS ESPERADOS………………………...……….22 9. IMPACTO ESPERADO A PARTIR DEL USO DE LOS RESULTADOS…....24 10. REFERENCIAS……………………………………………………………….....25 11. CRONOGRAMA DE ACTIVIDADES…………………………………………..28 12. PRESUPUESTO DEL PROYECTO.............................................................30spa
dc.formatpdfspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.language.isospaspa
dc.publisherUniversidad Militar Nueva Granadaspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.5/co/spa
dc.titleMutación BRAFV600E en citología tiroidea preoperatoria como identificador del compromiso ganglionar de compartimento central de los pacientes con carcinoma papilar de tiroides Bethesda V y VIspa
dc.typeinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.publisher.departmentFacultad de Medicinaspa
dc.type.localTrabajo de gradospa
dc.description.abstractenglishPapillary thyroid carcinoma is the most common type of endocrine cancer, with 85% of thyroid tumors, at the time of diagnosis, up to 45% of patients have lymph node involvement which has a great influence on the persistence and recurrence of the disease and up to 60% of the central compartment. BRAF is a mutation that occurs in half of papillary carcinomas of the thyroid, highly specific and correlates with the aggressiveness, recurrence and mortality of the carcinoma, which highlights the importance of knowing the status of same in patients. In patients with papillary thyroid carcinoma, determining the presence of positive BRAF will lead to the need for lymph node central emptying. There are no previous studies of the BRAF test in cytology and its correlation with positive lymph nodes in the central emptying of the neck.eng
dc.title.translatedBRAFV600E mutation in preoperative thyroid cytology as an identifier of central compartment ganglion involvement in patients with papillary thyroid carcinoma Bethesda V and VIspa
dc.subject.keywordsMUTACION BRAFV600Espa
dc.subject.keywordsCARCINOMA PAPILAR DE TIROIDESspa
dc.subject.keywordsVACIAMIENTO CENTRALspa
dc.publisher.programCirugía Oncológicaspa
dc.creator.degreenameEspecialista en Cirugía Oncológicaspa
dc.subject.decsENFERMEDADES DE LA TIROIDES
dc.subject.decsCANCER
dc.subject.decsGANGLIOS LINFATICOS
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyMedicina y Ciencias de la Salud - Cirugía de Cabeza y Cuellospa
dc.type.dcmi-type-vocabularyTextspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadasspa
dc.relation.references1. Tang K-T, Lee C-H. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc. 2010;73(3):113-28.spa
dc.relation.references2. Hwang J, Hee Shin J, Han B-K, Ko EY, Kang SS, Kim J-W, et al. Papillary thyroid carcinoma with BRAF V600E mutation: sonographic prediction. AJR Am J Roentgenol. 2010;194(5):425-30.spa
dc.relation.references3. Kim SK, Woo J-W, Lee JH, Park I, Choe J-H, Kim J-H, et al. Prophylactic central neck dissection might not be necessary in papillary thyroid carcinoma: analysis of 11,569 cases from a single institution. J Am Coll Surg. 2016;222(5):853-64.spa
dc.relation.references4. Lu J, Gao J, Zhang J, Sun J, Wu H, Shi X, et al. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol. 2015;8(1):793.spa
dc.relation.references5. Lee WS, Palmer BJA, Garcia A, Chong VE, Liu TH. BRAF mutation in papillary thyroid cancer: a cost-utility analysis of preoperative testing. Surgery. 2014;156(6):1569-78.spa
dc.relation.references6. Ward LS, Morari EC, Leite JL, Bufalo NE, Guilhen ACT, Araujo PPCd, et al. Identifying a risk profile for thyroid cancer. Arquivos Brasileiros de Endocrinologia & Metabologia. 2007;51(5):713-22.spa
dc.relation.references7. Ahn D, Sohn JH, Park JY. Surgical complications and recurrence after central neck dissection in cN0 papillary thyroid carcinoma. Auris Nasus Larynx. 2014;41(1):63-8.spa
dc.relation.references8. Zuñiga S, Sanabria A. Prophylactic central neck dissection in stage N0 papillary thyroid carcinoma. 2009;135(11):1087-91.spa
dc.relation.references9. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-62.spa
dc.relation.references10. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer. Cancer Res. 2003;63(7):1454-7.spa
dc.relation.references11. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid. 2007;17(5):381-8.spa
dc.relation.references12. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-501spa
dc.relation.references13. Park AY, Son EJ, Kim J-A, Youk JH, Park YJ, Park CS, et al. Associations of the braf v600e mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PloS one. 2014;9(10):e110868.spa
dc.relation.references14. Brzezianska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett. 2007;28(4):351-9.spa
dc.relation.references15. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004;61(2):239-43.spa
dc.relation.references16. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2006;65(3):364-8.spa
dc.relation.references17. Martín AM. Presencia de la mutación BRAFV600E en nódulos tiroideos, y su relación con el diagnóstico citológico y anatomopatológico de carcinoma de tiroides [Tesis]. Bogotá: Universidad Nacional de Colombia. Facultad de Medicina; 2015.spa
dc.relation.references18. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.spa
dc.relation.references19. Zúñiga S, Sanabria Á. Complicaciones y recurrencia en el tratamiento del carcinoma papilar de tiroides Experiencia del Instituto Nacional de Cancerología. Rev Colomb Cir. 2007:166.spa
dc.relation.references20. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.spa
dc.relation.references21. International Agency for Research on Cancer.The GLOBOCAN Project. 2012 [Internet]. [Revisado 28 de marzo de 2017]. Disponible en: http://globocan.iarc.fr/Default.aspx.spa
dc.relation.references22. Thyroid T. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 87-96.spa
dc.relation.references23. American Cancer Society. Cáncer de tiroides. [Internet]; 2012. [Revisado 29 de marzo de 2017]. Disponible en: https://old.cancer.org/acs/groups/cid/documents/webcontent/002324-pdf.pdf.spa
dc.relation.references24. Kondo T, Nakazawa T, Murata S-i, Kurebayashi J, Ezzat S, Asa SL, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol. 2007;38(12):1810-8.spa
dc.relation.references25. Kim B-A, Jee H-G, Yi JW, Kim S-J, Chai YJ, Choi JY, et al. Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation. Cancer Genomics Proteomics. 2017;14(1):53-67.spa
dc.relation.references26. Calò PG, Pisano G, Medas F, Marcialis J, Gordini L, Erdas E, et al. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World J Surg Oncol. 2014;12(1):152.spa
dc.relation.references27. Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683-9.spa
dc.relation.references28. Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab. 2015;100(4):1316-24.spa
dc.relation.references29. McHenry CR, Stulberg JJ. Prophylactic central compartment neck dissection for papillary thyroid cancer. Surg Clin North Am. 2014;94(3):529-40.spa
dc.relation.references30. Baek S-K, Jung K-Y, Kang S-M, Kwon S-Y, Woo J-S, Cho S-H, et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20(2):147-52.spa
dc.relation.references31. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20(1):47-52.spa
dc.relation.references32. Joo J-Y, Park J-Y, Yoon Y-H, Choi B, Kim J-M, Jo YS, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab. 2012;97(11):3996-4003.spa
dc.relation.references33. Fernandez IJ, Piccin O, Sciascia S, Cavicchi O, Repaci A, Vicennati V, et al. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg. . 2013;148(6):919-25.spa
dc.relation.references34. Yang Y, Chen C, Chen Z, Jiang J, Chen Y, Jin L, et al. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2014;81(2):282-8.spa
dc.relation.references35. Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, et al. Association of BRAF V600E mutation and microRNA expression with central lymph node metastases in papillary thyroid cancer: A prospective study from four endocrine surgery centers. Thyroid. 2016;26:532-42.spa
dc.relation.references36. Kurtulmus N, Ertas B, Saglican Y, Kaya H, Ince U, Duren M. BRAFV600E Mutation: Has it a role in cervical lymph node metastasis of papillary thyroid cancer. Eur Thyroid J. 2016;5(3):195-200.spa
dc.relation.references37. Liu C, Chen T, Liu Z. Associations between BRAF V600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol. 2016;14(1):241.spa
dc.relation.references38. Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope. 2011;121(3):487-91.spa
dc.relation.references39. Palestini N, Robecchi A. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer. Langenbecks Arch Surg (2008) 393:693-698.spa
dc.relation.references40. Dennis R, Medina A. Cálculo de tamaño de muestra. En: Ruíz A, Morillo L. Epidemiología Clínica. Investigación Clínica Aplicada. Bogotá: Editorial Médica Internacional; 2004. P.141-162spa
dc.relation.references41. Roche PC, Hsi ED. Immunohistochemistry-Principles and Advances. Manual of Clinical Laboratory Immunology, 6th edition. In: NR Rose, ed. ASM Press; 2002.spa
dc.relation.references42. Robinson TJ, Thomas S, Dinan MA, Roman S, Sosa JA, Hyslop T. How many lymph nodes are enough? assessing the adequacy of lymph node yield for papillary thyroid cancer. J Clin Oncol. 2016;34(28):3434-9.spa
dc.relation.references43. Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology: Springer; 2010.spa
dc.description.abstractotherO carcinoma papilífero da tireoide é o tipo mais comum de câncer endócrino, com 85% dos tumores da tireóide, no momento do diagnóstico, até 45% dos pacientes apresentam comprometimento linfonodal, o que tem grande influência na persistência e recidiva dos tumores. doença e até 60% do compartimento central. O BRAF é uma mutação que ocorre em metade dos carcinomas papilares da tireoide, altamente específicos e correlacionados com a agressividade, recidiva e mortalidade do carcinoma, o que evidencia a importância do conhecimento do estado dos mesmos nos pacientes. Em pacientes com carcinoma papilífero da tireoide, a determinação da presença de BRAF positivo levará à necessidade de esvaziamento central do linfonodo. Não há estudos prévios do teste BRAF em citologia e sua correlação com linfonodos positivos no esvaziamento central do pescoço.


Archivos en el ítem

Thumbnail
Nombre:
protocolo final repositorio.pdf
Tamaño:
709.9Kb
Formato:
PDF
Descripción:
trabajo principal
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

https://creativecommons.org/licenses/by-nc-nd/2.5/co/
Excepto si se señala otra cosa, la licencia del ítem se describe como https://creativecommons.org/licenses/by-nc-nd/2.5/co/